Neurocrine Biosciences Inc Stock Price, News & Analysis

Neurocrine Biosciences will present at the Stifel 2022 CNS Days virtual conference on March 28, 2022, at 3:30 p.m. Eastern Time. The presentation will be led by Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer. Attendees can access the live webcast on the company's website under the Investors section. A replay will be available about one hour post-event and archived for a month. Neurocrine specializes in therapies for neurological and neuroendocrine disorders, with an array of FDA-approved treatments and clinical programs.

Neurocrine Biosciences (Nasdaq: NBIX) announced participation in upcoming investor conferences. CEO Kevin Gorman will present at the Cowen 42nd Annual Virtual Health Care Conference on March 8, 2022, at 9:10 a.m. ET. He and CFO Matt Abernethy will also present at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET in Miami. Additionally, Kyle Gano will speak at the 1st Annual Needham Virtual Neuroscience Forum on the same day at 1:50 p.m. ET. Webcasts will be available on the company's website.

Neurocrine Biosciences (NBIX) reported strong financial results for Q4 and fiscal year 2021, with total revenues of $1.133 billion, up from $1.046 billion in 2020. The company achieved net product sales of $1.1 billion for INGREZZA, reflecting 25% growth in Q4 year-over-year. Despite a GAAP net loss of $7 million in Q4, its non-GAAP net income was $4.3 million. For 2022, NBIX guided INGREZZA sales between $1.25 billion and $1.35 billion, indicating approximately 20% growth. The firm is advancing a diverse pipeline with 12 mid-to-late-stage clinical programs.

Neurocrine Biosciences (Nasdaq: NBIX) announced a conference call to discuss its 2021 fourth quarter and year-end financial results on February 11, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The press release will precede this at 4:30 a.m. PT. Investors can access the call via domestic (800-895-3361) and international (785-424-1062) dial-in numbers, using Conference ID: NBIX. A replay will be available on Neurocrine's website following the event, highlighting the company's commitment to addressing neurological and psychiatric disorders through its diverse portfolio and ongoing clinical programs.

Neurocrine Biosciences (NBIX) reported preliminary net product sales of INGREZZA (valbenazine) for Q4 2021, totaling approximately $301 million, showing a 25% increase year-over-year. Total prescriptions rose by 32%. The company is on track to complete its commercial expansion by Q1 2022 and will provide full-year 2022 sales guidance on February 11, 2022. CEO Kevin Gorman highlighted the company's dedication to advancing a broad pipeline with 13 clinical programs expected to yield significant data in the next two years.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 40th Annual J.P. Morgan Healthcare Conference on Jan. 10, 2022, at 11:15 a.m. Eastern Time. CEO Kevin Gorman will lead the presentation. Investors can watch the live presentation via the company’s website, with a replay available about one hour post-event, archived for one month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with an FDA-approved portfolio addressing conditions like tardive dyskinesia and Parkinson's disease.

Neurocrine Biosciences (Nasdaq: NBIX) announced positive top-line results from its Phase 3 KINECT-HD study for valbenazine, targeting chorea in Huntington disease. The study achieved its primary endpoint, showing a placebo-adjusted mean reduction of 3.2 units in the Total Maximal Chorea (TMC) score (p < 0.0001). Secondary endpoints were also significant. No new safety concerns were reported, and no suicidal ideation emerged. The company plans to submit a supplemental new drug application to the FDA in 2022. Chorea affects about 30,000 adults in the U.S.

Neurocrine Biosciences (NASDAQ: NBIX) has appointed Jude Onyia, Ph.D., as the new Chief Scientific Officer. Dr. Onyia brings over 25 years of pharmaceutical industry experience, having served at Capsida Biotherapeutics and Eli Lilly & Co. where he contributed to over 60 clinical candidates leading to seven approved medicines. His leadership is expected to enhance Neurocrine's drug discovery efforts, focusing on developing treatments for neurological and endocrine disorders. CEO Kevin Gorman expressed confidence in Dr. Onyia's vision to advance the company's mission of alleviating patient suffering.

Neurocrine Biosciences (Nasdaq: NBIX) has entered a strategic collaboration with Sosei Group Corporation to develop muscarinic receptor agonists for treating schizophrenia and other neuropsychiatric disorders. The agreement grants Neurocrine rights to a portfolio of M4, M1, and dual agonists, including the advanced program HTL-0016878, a selective M4 agonist. Neurocrine plans to submit an IND application and initiate Phase 2 studies in 2022. Sosei will receive a $100 million upfront payment and up to $2.6 billion in milestone payments, plus royalties on future sales.